Preparation, Characterization and Anti-tumor Activity of Epirubicin Loaded Xyloglucan Nanoparticles for Nasal Delivery
DOI:
https://doi.org/10.37285/ijpsn.2014.7.1.11Abstract
The main objective of this study was to develop a polymeric drug delivery system for epirubicin, intended to be administered nasally, capable of improving the therapeutic index of the drug and devoid of the adverse effects of drug. To achieve this goal epirubicin loaded polymeric nanoparticles were prepare by the high-pressure homogenization method. Our results demonstrate that the methodology of preparation allowed the formation of nanometric (<200 nm), homogeneous and negatively charged particles which are suitable for nasal administration. The in vitro anti-tumor activity of xyloglucan-based nanoparticles developed in this work was assessed by using KBcells and compared to the in vitro anti-tumoral activity of the drug alone. These results demonstrate that incorporation of epirubicin in nanoparticles strongly enhances the cytotoxic effect of the drug.
Downloads
Metrics
Keywords:
Nanoparticles, Xyloglucan, Epirubicin, Nasal, Anti-tumor activity.
Downloads
Published
How to Cite
Issue
Section
References
Alam MI, Sarwar Beg, AbdusSamad, SanjulaBaboota, KanchanKohli, Javed Ali, AlkaAhuja and M. Akbar (2010). Strategy for effective brain drug delivery. Eur J Pharm Sci 40: 385–403.
Ali J, Ali M, Baboota S, Sahani JK, Ramassamy C, Dao L and Bhavna (2010). Potential of nanoparticulate drug delivery systems by intranasal administration. Curr Pharm Des 14: 1644-1653.
Costantino HR, Illum L, Brandt G, Johnson PH and Quay SC (2007). Intranasal delivery: Physicochemical and therapeutic aspects. Int J Pharm 337: 1-24.
Freitas C and Müller RH (1998). Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLNTM) dispersions. Int J Pharm 168: 221-229.
Glicksman, M. (Ed) (1986). Tamarind seed gum: In Food Hydrocolloids. CRC Press, Boca Raton, Florida. 3:191-202.
GraffCL and Pollack GM (2003). P-Glycoprotein attenuates brain uptake of substrates after nasal instillation. PharmRes 20: 1225-1230.
Jiang XG, Cui JB, Fang XL, Wei Y and Xi NZ (1995). Toxicity of drugson nasal mucocilia and the method of its evaluation. Acta Pharmacol Sin 30: 848-853.
Luppi B, Federica Bigucci, Angela Abruzzo, Giuseppe Corace, Teresa Cerchiara and Vittorio Zecchi (2010). Freeze-dried chitosan/pectin nasal inserts for antipsychotic drug delivery. Eur J Pharm Biopharm 75:381-387.
Luppi B, Federica Bigucci, Giuseppe Corace, Alice Delucca, Teresa Cerchiara, Milena Sorrenti, Laura Catenacci, Anna Maria Di Pietra and Vittorio Zecchi (2011). Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine. Eur J Pharm Sci 44: 559-565.
Pardridge WM (2007). Blood-brain barrier delivery. Drug Discov Today 12: 54-61.
Sakane T, Yamashita S, Yata N and Sezaki H (1999). Transnasal delivery of 5-fluorouracil to the brain in the rat. J Drug Target 7:233-40.
Shingaki T, Sakane T and Yamashita S (1999). Transnasal delivery of anticancer drugs to the brain tumor: a new strategy for brain tumor chemotherapy. Drug Delivery System 14:365-71.
Wang D, Gao Y and Yun L (2005). Study on brain targeting of raltitrexed following intranasal administration in rats. Cancer Chemother Pharmacol2 :1-8.
Wang F, Jiang X and Lu W (2003). Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats. Int J Pharm 63:1-7.
Wohlfart S, Khalansky A, Bernreuther C, Michaelis M, Cinatl J, Glatzel M and Kreuter J. (2011). Treatment of glioblastoma with poly (isohexyl cyanoacrylate) nanoparticles. Int J Pharm 415: 244-248.
Zhang H-Z, Fu-ping Gao, Ling-rong Liu, Xue-min Li, Zhi-min Zhou, Xin-du Yang and Qi-qing Zhang (2009). Pullulan acetate nanoparticles prepared by solvent diffusion method for epirubicin chemotherapy. Colloids and Surf B: Biointerface 71:19-26.
